NEW YORK – Veracyte on Friday priced an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of $74 per share.
The South San Francisco-based firm expects about $550 million in gross proceeds from the offering, before deducting underwriting discounts, commissions, and offering expenses.
In addition, Veracyte has granted the underwriters a 30-day option to purchase up to an additional 1,114,864 shares of its common stock at the public offering price, less underwriting discounts and commissions.